PROMISE
Ongoing study Official Study Title THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT Brief Description The goal of this clinical trial is to demonstrate the clinical benefit of early intervention with meropenem in adult patients of both sexes with suspected infection and
CLASSIFY
Ongoing study Official Study Title CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS Brief Description The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized
EMBRACE
Completed study Official Study Title EMapalumaB treatment foR Anticipated Clinical benefit in sepsis driven by the Interferon-Gamma Endotype (The EMBRACE trial) Brief Description In a recent analysis of 5,503 patients with sepsis meeting the Sepsis-3 definitions and coming from Germany, Greece and Italy randomized into one discovery set and one validation set, it was
POINT study
Personalised care for post-COVID-19 health Connect to the official POINT website Ongoing study Official Study Title A non-interventional, Prospective, cross-sectional study Of the INcidence of pulmonary, cardiovascular and renal system non-communicable complications associated with the post-acute phase of the infecTion by SARS-CoV-2 Brief Description POINT is an innovative research project funded
HOMI-LUNG CAP
A STRONG CONSORTIUM TO FILL THE GAP Pneumonia is a heart matter too (and viceversa) Connect to the official HOMI-LUNG CAP website Ongoing study Official Study Title A non-interventional, prospective, cross-sectional study of cardiovascular disease progression in survivors of community acquired pneumonia and lung infection by SARS-CoV-2 Brief Description HOMI-LUNG is
REACT
Ongoing study Official Study Title BiomarkeR-guided EArly Clarithromycin Treatment to prevent sepsis progression in community-acquired pneumonia: The REACT Randomized clinical trial Brief Description The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of